MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.

The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.